石藥集團(01093.HK):SYS 6017(帶狀皰疹m RNA疫苗)獲臨牀試驗批准
格隆匯2月7日丨石藥集團(01093.HK)宣佈,集團開發的SYS 6017( 帶狀皰疹m RNA疫苗 )("該產品")已獲得中華人民共和國國家藥品監督管理局批准,可以在中國開展臨牀試驗。
該產品由編碼水痘-帶狀皰疹病毒(VZV)糖蛋白E(g E蛋白)的m RNA分子包裹於脂質納米顆粒所構成,適用於預防帶狀皰疹的感染。臨牀前研究顯示,該產品可有效誘導體液免疫和細胞免疫應答。安全性評價數據亦表明該產品具有良好的安全性,在臨牀研究上有望表現出較少的不良反應。
全球普通人羣帶狀皰疹的發病率為3 – 5╱1,000人年。隨着年齡的增長,VZV特異性T細胞的增殖能力下降,細胞免疫減弱,長期潛伏於神經的VZV更容易被激活,因此帶狀皰疹的發病率隨着年齡的增長而上升:60歲為6 – 8╱1,000人年,80歲可達8 – 12╱1,000人年。近年來帶狀皰疹發病趨於年輕化,尤其是亞健康人羣以及腫瘤、愛滋病患者等免疫力低下人羣,患帶狀皰疹的風險顯著增加。目前,全球尚無針對VZV感染的m RNA疫苗上市。集團將全力推進該產品的臨牀研究工作,力爭該產品儘快上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.